Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles
Abstract Everolimus is an immunosuppressant with a small therapeutic index and large between‐patient variability. The area under the concentration versus time curve (AUC) is the best marker of exposure but measuring it requires collecting many blood samples. The objective of this study was to train...
Main Authors: | Marc Labriffe, Jean‐Baptiste Woillard, Jean Debord, Pierre Marquet |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-08-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12810 |
Similar Items
-
To be or not to be, when synthetic data meet clinical pharmacology: A focused study on pharmacogenetics
by: Jean‐Baptiste Woillard, et al.
Published: (2025-01-01) -
Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
by: Masaki Hirabatake, et al.
Published: (2022-09-01) -
Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia
by: Jinha Park, et al.
Published: (2023-11-01) -
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
by: Tomas Pascual, et al.
Published: (2017-01-01) -
Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects
by: Jiuhong Zha, et al.
Published: (2022-12-01)